The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Systems Endocrinology
Volume 15 - 2024 |
doi: 10.3389/fendo.2024.1424207
Plasma aldosterone concentrations elevation in hypertensive patients: the dual impact on hyperuricemia and gout
Provisionally accepted- People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
Background: Prior research has highlighted the association between uric acid (UA) and the activation of the renin-angiotensin-aldosterone system (RAAS). However, the specific relationship between aldosterone, the RAAS's end product, and UA-related diseases remains poorly understood. This study aims to clarify the impact of aldosterone on the development and progression of hyperuricemia and gout in hypertensive patients.Methods: Our study involved 34534 hypertensive participants, assessing plasma aldosterone concentration (PAC)'s role in UA-related diseases, mainly hyperuricemia and gout. We applied multiple logistic regression to investigate the impact of PAC and used restricted cubic splines (RCS) for examining the dose-response relationship between PAC and these diseases. To gain deeper insights, we conducted threshold analyses, further clarifying the nature of this relationship. Finally, we undertook subgroup analyses to evaluate PAC's effects across diverse conditions and among different subgroups.Results: Multivariate logistic regression analysis revealed a significant correlation between the occurrence of hyperuricemia and gout and the elevation of PAC levels.Compared to the first quartile (Q1) group, groups Q2, Q3, and Q4 all exhibited a significantly increased risk of occurrence. Moreover, the conducted RCS analysis demonstrated a significant nonlinear dose-response relationship, especially when PAC was greater than 14 ng/dL, with a further increased risk of hyperuricemia and gout.Finally, comprehensive subgroup analyses consistently reinforced these findings.This study demonstrates a close association between elevated PAC levels and the development of UA-related diseases, namely hyperuricemia and gout, in hypertensive patients. Further prospective studies are warranted to confirm and validate this relationship.
Keywords: Plasma aldosterone concentration, Hypertension, Uric Acid, Hyperuricemia, Gout
Received: 27 Apr 2024; Accepted: 03 Jul 2024.
Copyright: © 2024 Song, Cai, Hu, Zhu, Shen, Ma, Zhang, Ma, Zhou, Yang, Hong, Zhang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Junli Hu, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
Qing Zhu, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
Huimin Ma, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
Yingying Zhang, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
Rui Ma, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
Pan Zhou, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
Wenbo Yang, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
Jing Hong, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
Delian Zhang, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
Nanfang Li, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.